1) Data for 48 weeks were TG-C treatment group.
2) The p value of 48 weeks were calculated with a comparison between baseline to 48 weeks. Conclusions: In summary, this Phase IIb study indicated that TG-C treatment improved pain, sports activities, and quality of daily life in patients with knee OA when compared to the placebo control. Purpose: Injury to the meniscus may play a key role in the development of knee osteoarthritis (OA) and prior studies demonstrated that tear of the meniscus are more common in patients with knee OA. Tears present as severe pain, swelling and possible catching, difficulty on deep knee bending and locking of the knee in partial flexion. Basically, signs and symptoms of meniscal tears are those of any OA disease where the reduction of rheological properties of synovial fluid of the affected joint increases the susceptibility of the articular cartilage to damage. Clinical trials have demonstrated the efficacy of viscosupplementation in patients undergoing arthroscopic partial meniscectomy with results on pain reduction, better joint mobility and reduction of NSAIDs intake. On this basis we aim to investigate whether intra-articular injections of HYADD Ò 4-G (Hymovis Ò ) in patients with meniscal tears could improve symptoms and knee functionality so to avoid arthroscopy surgery to the patient. Methods: This is a single site, randomised, parallel groups, observerblind, investigator initiated study. Upon signature of the informed consent and satisfaction of all inclusion and exclusion criteria, each patient was randomly assigned to control group, receiving only conservative treatment or to HYADD Ò 4-G group. Conservative treatment consisted in use of an immobilizer brace, a combination of rest and ice, knee off-loading and acetaminophen as per patient's need. Patients allocated to HYADD Ò 4-G group in addition to the conservative treatment underwent to 2 injections of HYADD Ò 4-G two weeks apart: at visit V1 (day 0) and at visit V2 (day 14). Pain was investigated through a Visual Analogue Scale (VAS), knee pain stiffness and functionality through the WOMAC questionnaire. Secondary objectives are the evaluation of Quality of life by the SF-36 questionnaire, patient's and investigator's global assessment of the disease (PTGA/COGA), intake of analgesics and HYADD Ò 4-G safety. Meniscus tears were evaluated at baseline and at the following visits by magnetic resonance imaging scans. The study analyzed the relationship between the symptoms and the presence of a meniscus tears. Results: Fifty patients (25 in each of the two treatment groups) were enrolled in the study. All patients receiving HYADD Ò 4-G in addition to the conservative treatment completed the study, while only 17 out of the 25 patients in the control group attended the visit 4 (day 60). Reasons for discontinuing the study were lost to follow-up (4 patients), surgery before visit 3 (3 patients) and treatment failure (1 patient). Pain mean values decreases from 82.0 mm at baseline to 12.0 mm at V4 (day 60) in patients receiving HYADD Ò 4-G injection while in the control group VAS pain decreases from 83.6 mm to 57.9 at V4 (day 60). Among patients who completed the study a statistically significant difference was found between the groups at day 30 up to the end of the study at day 60 (P < 0.001). Results obtained on pain were confirmed by WOMAC assessment. WOMAC pain sub-score, stiffness and function showed the same trend. In particular considering WOMAC pain a statistical significant difference between two groups was found at day 30 and this difference persisted to day 60 (P < 0.001). No local or systemic serious adverse events were observed during the study. Five patients complained of local pain after injection. Four patients (3 included in control group and 1 in HYADD Ò 4-G group) reported a worsening of the baseline conditions; these events resulted in withdrawals from the study. Conclusion: Although it should be noted that the gold standard for the evaluation of meniscus injuries is arthroscopic surgery, this study demonstrates that patients who have been administered HYADD Ò 4-G can improve their symptoms relief since 14 days after the first treatment and this decrease was maintained up to 60 days. Symptoms relief together with MRI data are favourable to HYADD Ò 4-G study group, suggesting a relationship of meniscus injury pain reduction and physical improvement in knee. In conclusion based on this study HYADD Ò 4-G seems to be indicated for the treatment of pain in patients affected by meniscal tear or degenerative signal but further investigations need to be conducted on other symptoms related to this condition to confirm these promising data. Objective: Improving the accuracy of high tibial osteotomy not only in the coronal plane but with considering it as a three dimension procedure can give better long term results in cases of medial compartment osteoarthritis associated with varus deformity and minimize the obstacles faced in future total knee replacement (TKR). Design: Two different techniques of high tibial osteotomy: the opening wedge (OWO) and the hemicallotasis osteotomy (HCO) were compared clinically in a prospective randomized clinical trial that was held in Ain Shams University hospitals in the period between December 2010 to The studies had to include a PRGF group and a control group (Hyaluronic acid, placebo, or another PRP), and the design had to be a comparative retrospective study or randomized controlled trial (RCT). Pre-and post-treatment measures of joint pain, reduced function and stiffness were evaluated using WOMAC, KOOS, IKCD, LEQUESNE, or OMERAT OARSI responders, with a follow-up of at least 4 weeks. Studies conducted using methods other than PRGF (such us double centrifugation, presence of leukocytes, platelet activation by bovine thrombin) to elaborate the product treatment group, were excluded. Outcomes were categorized by types and by pre-and post-treatment numbers, and median, or mean values (SD) were extracted. Dichotomic variables were expressed by determination of absolute and relative frequencies and the measure of effect was calculated by ascertaining the relative risk or odds ratio with their respective 95% confidence intervals. Quantitative variables were summarized by using the mean and standard deviation with intervals confidence at 95%. The quality assesment encompassed study methods, participants, experimental intervention, and control treatment. Overall, the risk of bias was categorized as low, unclear, or high risk based on random sequence generation, allocation concealment, blinding, incomplete outcome data, and selective reporting.
RANDOMIZED, SINGLE CENTER, OBSERVER-BLIND, PARALLEL-GROUP TRIAL TO EVALUATE THE SAFETY AND EFFECTIVENESS OF HYADD
Results: The literature research yielded 91 citations, but only publications using eligible PRGF met the inclusion criteria, consisting of 3 RCTs, 1 prospective and 1 retrospective analysis (n ¼ 5). Two studies were rated as having a low risk of bias, and the remaining three studies as having high risk of bias. In two randomized clinical trials, it was observed that after six months of treatment the number of patients with a pain reduction of more than 50% was significantly higher in the group treated with PRGF than in the control group (HA). In two other studies (one retrospective and one prospective) the patients treated with PRGF showed a significant pain reduction compared with the patients treated with HA (WOMAC and VAS scale respectively). The remaining variables (WOMAC scale for pain, function, and stiffness, LEQUESNE, KOOS, scale and OMERAT OARSI responders) showed a statistically significant superiority of the group treated with PRGF in two RCT (Vaquerizo et al 2013, and Say et al 2013) .
Conclusions:
The current clinical evidence suggests that pain reduction of PRGF intra-articular infiltrations in patients with knee OA is significantly higher compared with HA, and lasting for a longer period of time (24 weeks after the last infiltration). Despite the high risk of bias of the other three studies, their results are consistent with those coming from the two RCT. There exist three key limitations in this review: the heterogeneity of the studies that met the inclusion criteria, the small number of publications included in the study, and the absence of a placebo in the control group. Purpose: To evaluate the therapeutic effect of a low cost, flexible nonheeled shoe on the WOMAC domains and paracetamol intake of elderly women with knee OA. Methods: A randomized, parallel and controlled clinical trial, with blind assessor was carried out. Fifty-six elderly women with knee OA graded 2 or 3 (Kellgren and Lawrence), assessed at baseline (T0), after three (T3) and after six months (T6), were randomly allocated into the intervention group (IG, n ¼ 28) or the control group (CG, n ¼ 28). We adopted the WOMAC pain as a primary outcome, and stiffness, function, and total WOMAC score, and paracetamol intake as the secondary outcomes. As intervention, the patients wore a minimalist, flexible and low-cost shoe (Moleca Ò shoe; Calçados Beira Rio S.A., Novo Hamburgo, RS, Brazil) for average daily usage time of 7 h 40 min. This intervention shoe is a women's double canvas flexible flat walking footwear without heels, and with a 5-mm anti-slip rubber sole. Paracetamol (500 milligrams), as a rescue medication, was allowed for both groups only in case of pain. The time effects (baseline, 3 and 6 months) of group (IG and CG) and interaction (time and group) were tested by two-way casewise ANOVA. Results: The IG showed an improvement in pain (effect size between-group of 1.41), function (effect size of 1.22), and stiffness (effect size of 0.76) in WOMAC. The within-group results show that the IG improved the WOMAC pain by 51% (p ¼ 0.001) at T3 and 66% (p ¼ 0.001) at T6. The CG improved the WOMAC pain by 34% (p ¼ 0.001) at T3 and 28% (p ¼ 0.001) at T6. The IG improved the WOMAC stiffness by 55% (p ¼ 0.001) versus the CG that worsened 22% (p ¼ 0.001) at T3; at T6, the IG presented a reduction of 62% (p ¼ 0.001) for WOMAC stiffness while, in the CG, the reduction was only by 15% (p ¼ 0.001). The IG increased the WOMAC function by 52% (p ¼ 0.001) at T3 and 62% (p ¼ 0.001) at T6. In the CG, this variable was improved by 29% (p ¼ 0.001) at T3 and 19% (p ¼ 0.001) at T6. In the IG, WOMAC total score was improved by 53% (p ¼ 0.001) at T3 and 62.4% (p ¼ 0.019) at T6. In CG the improvement was of 26% (p ¼ 0.001) at T3 and 19% (p ¼ 0.001) at T6. The CG increased significantly the intake of rescue medication throughout the study, which possibly influenced their pain reduction and function improvement. The IG showed a slight increase in the paracetamol intake at the end of the 1st, 2nd and 3rd month; nevertheless, in the 4th, 5th and 6th month, the paracetamol intake was again similar to the initial assessment. From the 2nd to 6th month paracetamol intake was significantly higher in CG compared to IG. Conclusion: We can recommend the use of this low cost minimalist shoe as another conservative mechanical treatment that aims to minimize pain, improve functional aspects, and reduce the rescue medication intake. 
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